Joel A Sincavage
Supervisory Patent Examiner (ID: 11124, Phone: (571)272-2610 , Office: P/2910 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2911, 2900, 2901, 2910 |
Total Applications | 4082 |
Issued Applications | 4006 |
Pending Applications | 1 |
Abandoned Applications | 75 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 13248945
[patent_doc_number] => 10137144
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-11-27
[patent_title] => Methods and compositions for the activation of gamma-delta T-cells
[patent_app_type] => utility
[patent_app_number] => 15/904131
[patent_app_country] => US
[patent_app_date] => 2018-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 25643
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 167
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904131
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/904131 | Methods and compositions for the activation of gamma-delta T-cells | Feb 22, 2018 | Issued |
Array
(
[id] => 13916995
[patent_doc_number] => 10202605
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-02-12
[patent_title] => Methods of identifying and treating poor-prognosis cancers
[patent_app_type] => utility
[patent_app_number] => 15/901174
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 41423
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901174
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/901174 | Methods of identifying and treating poor-prognosis cancers | Feb 20, 2018 | Issued |
Array
(
[id] => 15268075
[patent_doc_number] => 20190382771
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-19
[patent_title] => ASYMMETRIC siRNA FOR INHIBITING EXPRESSION OF MALE PATTERN HAIR LOSS TARGET GENE
[patent_app_type] => utility
[patent_app_number] => 16/486833
[patent_app_country] => US
[patent_app_date] => 2018-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486833
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/486833 | Asymmetric siRNA for inhibiting expression of male pattern hair loss target gene | Feb 20, 2018 | Issued |
Array
(
[id] => 13867435
[patent_doc_number] => 20190030058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-01-31
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
[patent_app_type] => utility
[patent_app_number] => 15/892560
[patent_app_country] => US
[patent_app_date] => 2018-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15892560
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/892560 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT | Feb 8, 2018 | Abandoned |
Array
(
[id] => 13339563
[patent_doc_number] => 20180221321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-09
[patent_title] => METHODS AND PRODUCTS RELATED TO GLUTAMINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 15/890220
[patent_app_country] => US
[patent_app_date] => 2018-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890220
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/890220 | Methods and products related to glutaminase inhibitors | Feb 5, 2018 | Issued |
Array
(
[id] => 14199459
[patent_doc_number] => 10266826
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-23
[patent_title] => Modulation of BCL11A for treatment of hemoglobinopathies
[patent_app_type] => utility
[patent_app_number] => 15/888350
[patent_app_country] => US
[patent_app_date] => 2018-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 53
[patent_no_of_words] => 24188
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15888350
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/888350 | Modulation of BCL11A for treatment of hemoglobinopathies | Feb 4, 2018 | Issued |
Array
(
[id] => 15666869
[patent_doc_number] => 10597655
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-24
[patent_title] => Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
[patent_app_type] => utility
[patent_app_number] => 15/887228
[patent_app_country] => US
[patent_app_date] => 2018-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 23
[patent_no_of_words] => 4237
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15887228
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/887228 | Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor | Feb 1, 2018 | Issued |
Array
(
[id] => 16870517
[patent_doc_number] => 20210163984
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => COMPOSITIONS FOR REDUCING SARCOLIPIN EXPRESSION AND PREVENTING AND TREATING MUSCULAR DYSTROPHY AND CARDIOMYOPATHY AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/479838
[patent_app_country] => US
[patent_app_date] => 2018-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479838
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/479838 | Compositions for reducing sarcolipin expression and preventing and treating muscular dystrophy and cardiomyopathy and methods of use | Jan 21, 2018 | Issued |
Array
(
[id] => 15321581
[patent_doc_number] => 20200001120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 16/475710
[patent_app_country] => US
[patent_app_date] => 2018-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14279
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475710
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/475710 | APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONS | Jan 4, 2018 | Abandoned |
Array
(
[id] => 16197394
[patent_doc_number] => 10722530
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-28
[patent_title] => Methods of diagnosing and treating cancer
[patent_app_type] => utility
[patent_app_number] => 15/854345
[patent_app_country] => US
[patent_app_date] => 2017-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 50
[patent_no_of_words] => 26957
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15854345
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/854345 | Methods of diagnosing and treating cancer | Dec 25, 2017 | Issued |
Array
(
[id] => 13413897
[patent_doc_number] => 20180258491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => BIOMARKERS ASSOCIATED WITH BRM INHIBITION
[patent_app_type] => utility
[patent_app_number] => 15/853699
[patent_app_country] => US
[patent_app_date] => 2017-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20651
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15853699
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/853699 | BIOMARKERS ASSOCIATED WITH BRM INHIBITION | Dec 21, 2017 | Abandoned |
Array
(
[id] => 13814729
[patent_doc_number] => 10184125
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-01-22
[patent_title] => Modulation of TMPRSS6 expression
[patent_app_type] => utility
[patent_app_number] => 15/850093
[patent_app_country] => US
[patent_app_date] => 2017-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21856
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15850093
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/850093 | Modulation of TMPRSS6 expression | Dec 20, 2017 | Issued |
Array
(
[id] => 12751273
[patent_doc_number] => 20180142258
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-24
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 15/850937
[patent_app_country] => US
[patent_app_date] => 2017-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15850937
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/850937 | Methods and compositions for the activation of gamma-delta T-cells | Dec 20, 2017 | Issued |
Array
(
[id] => 12751270
[patent_doc_number] => 20180142257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-05-24
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 15/849062
[patent_app_country] => US
[patent_app_date] => 2017-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21428
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849062
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/849062 | Methods and compositions for the activation of gamma-delta T-cells | Dec 19, 2017 | Issued |
Array
(
[id] => 16695538
[patent_doc_number] => 10946107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-16
[patent_title] => Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 15/841486
[patent_app_country] => US
[patent_app_date] => 2017-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 48542
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841486
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/841486 | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof | Dec 13, 2017 | Issued |
Array
(
[id] => 16305552
[patent_doc_number] => 10774331
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-15
[patent_title] => Methods of inducing insulin production
[patent_app_type] => utility
[patent_app_number] => 15/837377
[patent_app_country] => US
[patent_app_date] => 2017-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 27959
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837377
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/837377 | Methods of inducing insulin production | Dec 10, 2017 | Issued |
Array
(
[id] => 15800809
[patent_doc_number] => 20200123547
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => NUCLEIC ACID-BASED ASSEMBLY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/467151
[patent_app_country] => US
[patent_app_date] => 2017-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27074
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16467151
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/467151 | NUCLEIC ACID-BASED ASSEMBLY AND USES THEREOF | Dec 6, 2017 | Pending |
Array
(
[id] => 16277060
[patent_doc_number] => 10760077
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-01
[patent_title] => Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
[patent_app_type] => utility
[patent_app_number] => 15/833891
[patent_app_country] => US
[patent_app_date] => 2017-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 43
[patent_no_of_words] => 18549
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 95
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15833891
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/833891 | Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes | Dec 5, 2017 | Issued |
Array
(
[id] => 15114461
[patent_doc_number] => 20190343863
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-14
[patent_title] => MODULATION OF LNC05 EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/465083
[patent_app_country] => US
[patent_app_date] => 2017-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16465083
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/465083 | Modulation of Lnc05 expression | Nov 30, 2017 | Issued |
Array
(
[id] => 13479667
[patent_doc_number] => 20180291376
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-11
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
[patent_app_type] => utility
[patent_app_number] => 15/818073
[patent_app_country] => US
[patent_app_date] => 2017-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818073
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/818073 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING | Nov 19, 2017 | Abandoned |